In the interview, Michal Zahradnicek describes his journey from building successful IT companies to investing more than CZK 1.5 billion into biotechnologies and regenerative medicine. Primecell has since grown into one of the key players in Europe, operating the largest tissue bank on the continent and mastering the full value chain from tissue collection and processing to advanced cell and gene based therapies.

A significant part of the conversation is dedicated to the growing global interest in longevity and scientifically grounded regenerative medicine. Primecell’s teams work on clinically validated solutions for chronic wounds, osteoarthritis and immunological and neurological conditions, leveraging mesenchymal stem cells, exosomes and other advanced modalities.

LIFE BioCEEd is presented as a natural extension of this ecosystem. The fund was created to systematically search for high potential medical and biotech research projects across CEE, help structure technology transfer and support their path from laboratory to market. With an initial capital commitment of CZK 500 million and the possibility to scale through co investments, LIFE BioCEEd aims to:

🔹Identify outstanding research in medicine, biology and life sciences across the region

🔹Provide expertise in regulatory strategy, IP and clinical development

🔹Build companies and partnerships around technologies with clear patient impact and global potential

The interview also highlights a structural gap in technology transfer in Central and Eastern Europe: many excellent projects remain hidden in academic laboratories and are not actively scouted by investors. LIFE BioCEEd was founded precisely to bridge this gap and act as a catalyst between universities, hospitals and international capital.

The full article is available on the Forbes Czechia website: https://forbes.cz/zahradnicek-miliardari-od-nas-chteji-omlazovaci-kury-rika-michal-z-firmy-primecel/